A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study

Radiotherapy and Oncology

Volumn 113, Issue 1, 2014, Pages 77-83

  Ladra, Matthew M ^a   Edgington, Samantha K ^a   Mahajan, Anita ^b   Grosshans, David ^b   Szymonifka, Jackie ^a   Khan, Fazal ^a   Moteabbed, Maryam ^a   Friedmann, Alison M ^a   MacDonald, Shannon M ^a   Tarbell, Nancy J ^a   Yock, Torunn I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Pediatrics; Protons; Rhabdomyosarcoma

Indexed keywords

PROTON;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DOSIMETRY; EVENT FREE SURVIVAL; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LIMB; MAJOR CLINICAL STUDY; ORBIT CANCER; ORGANS AT RISK; OVERALL SURVIVAL; PELVIS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON THERAPY; RADIATION DOSE; RHABDOMYOSARCOMA; TREATMENT PLANNING; TRUNK; UROGENITAL TRACT CANCER; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; CONSERVATIVE TREATMENT; FEMALE; HEAD AND NECK NEOPLASMS; MALE; MULTICENTER STUDY; PELVIC NEOPLASMS; PROCEDURES; RADIOMETRY; THORACIC NEOPLASMS;

CHILD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; ORGAN SPARING TREATMENTS; PELVIC NEOPLASMS; PROSPECTIVE STUDIES; PROTON THERAPY; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RHABDOMYOSARCOMA; THORACIC NEOPLASMS;

EID: 84922669253     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.08.033     Document Type: Article

References (43)

1. Ries LAG, SEER Program (National Cancer Institute (U.S.)). Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. In: Lynn A, Gloecker Ries, et al., editors. Bethesda, MD: National Cancer Institute, SEER Program; 1999.
2. Miller RW, Young Jr JL. Novakovic B: Childhood cancer. Cancer 1995; 75: 395-405.
3. Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J Clin Oncol 2009; 27: 5182-8.
4. Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2011; 29: 1312-8.
5. Merks JH, De Salvo GL, Bergeron C, et al. Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups. Ann Oncol 2014; 25: 231-6.
6. Breneman J, Meza J, Donaldson SS, et al. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Int J Radiat Oncol Biol Phys 2012; 83: 720-6.
7. Minn AY, Lyden ER, Anderson JR, et al. Early treatment failure in intermediaterisk rhabdomyosarcoma: results from IRS-IV and D9803 - a report from the Children's Oncology Group. J Clin Oncol 2010; 28: 4228-32.
8. Wolden SL, Anderson JR, Crist WM, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I-III. J Clin Oncol 1999; 17: 3468-75.
9. Rubin P, Constine L, Williams J. Late effects of cancer treatment: radiation and drug toxicity, in principles and practice of radiation oncology. In: Perez CBL, editor. Principles and practice of radiation oncology. Philadelphia: Lippincott- Raven Publishers; 1998. p. 155-211.
10. Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5: 399-408.
11. Miralbell R, Lomax A, Cella L, et al. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002; 54: 824-9.
12. Cotter SE, McBride SM, Yock TI. Proton radiotherapy for solid tumors of childhood. Technol Cancer Res Treat 2012; 11: 267-78.
13. Langendijk JA, Lambin P, De Ruysscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the modelbased approach. Radiother Oncol 2013; 107: 267-73.
14. Simone 2nd CB, Ly D, Dan TD, et al. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. Radiother Oncol 2011; 101: 376-82.
15. Kozak KR, Adams J, Krejcarek SJ, et al. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 2009; 74: 179-86.
16. Yock T, Schneider R, Friedmann A, et al. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys 2005; 63: 1161-8.
17. Childs SK, Kozak KR, Friedmann AM, et al. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects. Int J Radiat Oncol Biol Phys 2012; 82: 635-42.
18. Cotter SE, Herrup DA, Friedmann A, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011; 81: 1367-73.
19. Paganetti H, Niemierko A, Ancukiewicz M, et al. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys 2002; 53: 407-21.
20. Ladra MM, Szymonifka J, Yock TI, et al. Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma. J Clin Oncol 2014; 32 [in press].
21. De Ruysscher D, Mark Lodge M, Jones B, et al. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol 2012; 103: 5-7.
22. Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol 2010; 95: 23-31.
23. Merchant TE, Rose SR, Bosley C, et al. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol 2011; 29: 4776-80.
24. Vance ML, Mauras N. Growth hormone therapy in adults and children. N Engl J Med 1999; 341: 1206-16.
25. Gilchrist FJ, Murray RD, Shalet SM. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf) 2002; 57: 363-70.
26. Wass JA, Reddy R. Growth hormone and memory. J Endocrinol 2010; 207: 125-6.
27. Nieves-Martinez E, Sonntag WE, Wilson A, et al. Early-onset GH deficiency results in spatial memory impairment in mid-life and is prevented by GH supplementation. J Endocrinol 2010; 204: 31-6.
28. Mailhot Vega RB, Kim J, Bussiere M, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer 2013; 119: 4299-307.
29. Budson AE. Understanding memory dysfunction. Neurologist 2009; 15: 71-9.
30. Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101: 946-58.
31. Bessell EM, Henk JM, Whitelocke RA, et al. Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma. Eye (Lond) 1987; 1: 90-6.
32. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 2011; 79: 650-9.
33. Bhandare N, Moiseenko V, Song WY, et al. Severe dry eye syndrome after radiotherapy for head-and-neck tumors. Int J Radiat Oncol Biol Phys 2012; 82: 1501-8.
34. Hall P, Granath F, Lundell M, et al. Lenticular opacities in individuals exposed to ionizing radiation in infancy. Radiat Res 1999; 152: 190-5.
35. Brooks Jr HL, Meyer D, Shields JA, et al. Removal of radiation-induced cataracts in patients treated for retinoblastoma. Arch Ophthalmol 1990; 108: 1701-8.
36. Hoehn ME, Irshad F, Kerr NC, et al. Outcomes after cataract extraction in young children with radiation-induced cataracts and retinoblastoma. J AAPOS 2010; 14: 232-4.
37. Green DM, Sklar CA, Boice Jr JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2374-81.
38. Friedman DL, Constine L. Late effects of cancer treatment. In: Halperin E, editor. Pediatric radiation oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2011. p. 353-95.
39. Ash P. The influence of radiation on fertility in man. Br J Radiol 1980; 53: 271-8.
40. Chung CS, Yock TI, Nelson K, et al. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013; 87: 46-52.
41. Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012; 84: 449-55.
42. Hoppe BS, Flampouri S, Su Z, et al. Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys 2012; 83: 260-7.
43. Weber DC, Trofimov AV, Delaney TF, et al. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys 2004; 58: 1596-606.